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ABSTRACT  
The School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin hosted the 1
st
 
Workshop on Drug Transporters in the Lungs in September 2016 to discuss the impact of 
transporters on pulmonary drug disposition and their roles as drug targets in lung disease. 
The workshop brought together about 30 scientists from academia and pharmaceutical 
industry from Europe and Japan and addressed the primary questions: What do we know 
today, and what do we need to know tomorrow about transporters in the lung? The three 
themes of the workshop were: (1) techniques to study drug transporter expression and 
actions in the lungs; (2) drug transporter effects on pulmonary pharmacokinetics – case 
studies; and (3) transporters as drug targets in lung disease.  
Some of the conclusions of the workshop were: suitable experimental models that allow 
studies of transporter effects are available; data from these models convincingly show a 
contribution of both uptake and efflux transporters on pulmonary drug disposition; the 
effects of transporters on drug lung PK is now better conceptualised; some transporters are 
associated with lung diseases. However, more work is needed to establish which of the 
available models best translate to the clinical situation. 
 
KEYWORDS: Absorption; Computational ADME; Efflux pumps; In vitro models; Organic cation 
transporters; P-glycoprotein; Peptide Transporters; Pulmonary delivery/absorption; ABC 
Transporters; Organic anion-transporting polypeptide transporters  
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LIST OF ABBREVIATIONS  
ASP
+
, 4-(4-(dimethylamino) styryl)-N-methylpyridinium iodide; BAL, broncho-alveolar lavage; 
BCRP, breast cancer resistance protein; CDF, carboxy-dichlorofluorescein; COX, 
cyclooxygenase; ECF, extra-cellular fluid; ELF, epithelial lining fluid; HPAEpiC, human primary 
alveolar epithelial cells; HTEpiC, human tracheal epithelial cells; IPRL, isolated and perfused 
rat lung; LC-MS/MS, liquid chromatography–linked tandem mass spectrometry; MDR, 
multidrug resistance; MRP, multidrug resistance-associated protein; OAT, organic anion 
transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; 
NHBE, normal human bronchial epithelial cells; PEPT; peptide transporter; PG, 
prostaglandin; P-gp, P-glycoprotein; PBPK, physiologically based pharmacokinetics; PK, 
pharmacokinetics; PKC, protein kinase C; SLC; solute carrier; SV, simian virus; Vu,lung, volume 
of distribution in the lung 
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INTRODUCTION  
In pre-clinical drug development, drug transporter interactions are routinely studied in 
epithelia of the intestine, liver and kidney as well as the endothelium of the blood–brain 
barrier. Transporter effects in pulmonary drug disposition have been hypothesised for 
several years (reviewed, e.g. in 14, 15, 31 and 32). The vast majority of data that are 
available were generated using organotypic in vitro or ex vivo models and are consistent 
with the idea that drug absorption from the lungs is not exclusively mediated by passive 
diffusion. These initial studies confirmed the expression of drug transporters in lung tissues 
in situ and/or demonstrated transporter-related effects in cultured cells, but the translation 
of these data into clinical practice is still missing.  
It was the aim of this workshop to bring together a group of international experts who shall 
summarise and discuss the available information on lung drug transporters and to find a 
consensus on what steps to take next, in order to advance the field. The workshop had 
three main themes, i.e. (1) techniques to study drug transporter expression and actions in 
the lungs; (2) drug transporter effects on pulmonary pharmacokinetics (PK) – case studies; 
and (3) Transporters as drug targets in lung disease.  
This report briefly summarises the lectures given at the workshop. In the first part, existing 
methods and techniques to study the expression and action of pulmonary transporters will 
be discussed, ranging from targeted proteomics to cell-based in vitro systems to complex ex 
vivo models. In the second part, case studies will highlight the impact of specific 
transporters on the distribution of pulmonary administered drugs and in the final section, 
the evidence on drug transporter contribution to lung disease onset and/or progression will 
be summarised.  
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Techniques to study drug transporter expression and actions in the lungs 
Characterisation of lung transporters in lung tissues and primary cultured and immortalised 
lung cells based on quantitative targeted absolute proteomics 
Membrane permeability is a key factor in drug absorption, distribution, elimination and 
efficacy, therefore, knowledge of function, expression and localisation of membrane 
transporter proteins is important for rational drug discovery and development. A highly 
selective, sensitive and simultaneous protein quantification method has been developed on 
the basis of separation and identification of protein digests by liquid chromatography–linked 
tandem mass spectrometry (LC-MS/MS) with selective reaction monitoring SRM mode.
1
 
Targeted peptides for LC-MS/MS analysis were selected only from amino acid sequences 
based on in silico selection criteria.
1
 This protein quantification method has been applied for 
several studies, e.g. the analysis of transporter protein expression difference in organs,
1
 
animal species
2
 and disease models,
3
 validation of in vitro models,
4
 validation of humanised 
animal models,
5
 prediction of in vivo drug absorption
6
 and distribution.
3
  
The lung is a very important organ for local drug targeting and systemic delivery. QTAP 
studies have revealed transporter protein expression in human lung tissues,
4
 primary 
cultured cells
4,7
 and immortalised cell lines.
8
 Nineteen transporters (i.e. MDR1, MRP1, 
MRP3, MRP4, MRP5, MRP6, MRP8, BCRP, OCT1, OCT2, OCTN1, OAT2, OAT3, OAT4, PEPT2, 
OATP1A2, OATP1B3, OATP2B1 and PGT/OATP2A1) in human lung tissue has been confirmed 
by QTAP LC-MS/MS analysis.
4
 The most abundantly expressed protein was OCTN1.
4
 High 
expression of MRP1, BCRP and PEPT2 protein was also revealed.
4
 Interestingly, MRP8 
protein expression in female lung was 8-fold higher than that in male specimens, 
demonstrating a significant gender difference of transporter protein expression.
4
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When commercially available human pulmonary epithelial cells (i.e. tracheal (HTEpiCs), 
bronchial (NHBEs) and alveolar (HPAEpiCs)) in primary culture were studied, 9 transporters 
(i.e. MRP1, MRP4, MRP5, MRP6, OCT1, OCT2, OCTN1, OATP1B3 and OATP2B1), 14 
transporters (i.e. MRP1, MRP2, MRP3, MRP4, MRP5, MRP6, BCRP, OCT1, OCT2, OCTN1, 
OAT3, PEPT2, OATP1B3 and OATP2B1) and 8 transporters (i.e. MDR1, MRP1, MRP4, MRP5, 
MRP6, OCT2, OCTN1 and OATP2B1) were found in detectable quantities in HTEpiCs, NHBEs 
and HPAEpiCs, respectively.
4
 OATP2B1 was detected in all cell types and therefore, might 
have important physiological roles and could be a useful target transporter for pulmonary 
drug delivery. MRP1 expressed abundantly in bronchi and alveoli, exhibited an 18-fold 
maximal inter-individual difference in the bronchial region among 5 donors.
4
 Inter-individual 
differences in apparent efflux activities evaluated by the steady state cell-to-medium ratio 
of carboxy-dichlorofluorescein (CDF), a model substrate of MRPs in HTEpiCs, NHBEs and 
HPAEpiCs correlated well with MRP1 protein expression levels in the respective cells 
examined.
7
 OCTN1 expression in primary cultured cells of all three different regions was 
similar to that of lung tissue. The maximum uptake rate of the organic cation, 4-(4-
(dimethylamino) styryl)-N-methylpyridinium iodide (ASP
+
) into HTEpiCs, NHBEs and 
HPAEpiCs correlated well with OCTN1 transporter protein levels in the plasma membrane 
fraction of cells from 5 different donors.
7
  
QTAP studies were also been performed for 5 commonly used respiratory epithelial cell 
lines.
8
 Interestingly, OCTN1 protein expression in NCI-H441 was shown to be most closely 
resembling that in primary cells. Similarities and differences of transporter protein 
expression were shown between the immortalised cell lines and the primary cultured cells, 
showing limitations of the use of immortalised cell lines.
8
 In conclusion, quantitative 
targeted absolute proteomics is a useful tool to characterise drug transporter protein 
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expression in lung tissues and to compare primary cultured cells and immortalised cell lines 
in the context of inhalation biopharmaceutics. 
 
Cell culture models of the air-blood barrier  
Cell culture models are a relatively quick and simple means to study mechanisms of drug 
disposition at the molecular level. Free of the limitations of complex organ systems or 
indeed living subjects, uptake, transport, metabolism and toxicity can hence be studied in 
vitro.
9,10
 On the other hand, these models have obvious shortcomings regarding, for 
example their lack of clearance mechanisms or reduction to mostly a singular cell type, 
which needs to be considered when interpreting data generated in in vitro assays.  
A number of questions need to be addressed when deciding which in vitro model to use:  
• Should the model be of human or animal origin? Animal-derived (primary) cells are 
easier to obtain, but due to species differences they should mainly be used to 
support in vivo or ex vivo data generated in the same species.  
• Should freshly isolated cells in primary culture be used or a continuously growing cell 
line? Primary cells have arguably the closest resemblance to the in vivo situation, but 
they are associated with considerably higher cost and effort and eventually will 
dedifferentiate. Continuously growing cell line, either of cancerous origin or 
immortalised are generally easier to obtain and can be kept in culture for several 
passage numbers, but they might differ significantly from their original cell types.  
• Also important is the choice of culture conditions. Can the cells be grown at an air-
liquid interface or do they require submersed culture conditions?
11,12
 Which medium 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
and medium supplements should be used and what type of extracellular matrix? For 
how long can the cells be kept in culture? What is the impact of oxygen pressure? In 
any case, cell lines that have not been used in a biopharmaceutical context require a 
thorough characterisation. 
The ideal in vitro model would have a cellular phenotype similar to the cell in situ, which in 
the case of respiratory epithelium, implies the ability to grow to confluent, polarised cell 
layer(s), a mixed population of cell types, functional cilia (trachea/bronchi/bronchioles), 
mucus secretion (trachea/bronchi/bronchioles) and/or surfactant production 
(bronchioles/alveoli) and the expression of drug transporters and metabolic enzymes at the 
same level and activity as the corresponding barrier. Many of the widely used cancer-
derived cell lines, i.e. Calu-3, A549, NCI-H441 and NCI-H292 have significant shortcomings in 
many of the above mentioned aspects. Similarly, the first generation of simian virus (SV)40 
large T antigen-immortalised cell lines, e.g. 16HBE14o- and BEAS-2B often present 
phenotypes different from the original cell type. More recently generated immortalised cell 
lines such as NuLi-1, UNCN1T - 3T, VA10, BCi-NS1.1 and hAELVi appear to better resemble 
the native cells, but most of them have not yet been sufficiently characterised in term of 
biopharmaceutical applications.
13, 106-109
 
In vitro models of lung epithelium have been extensively used for uptake and transport 
studies. P-glycoprotein and organic cation transporters are probably the most studied 
transporters, but also MRPs, peptide transporters and several others have been 
investigated.
14,15
 Absorption across cell monolayers has been compared to drugs’ 
physicochemical parameters (e.g. log P, polar surface area), to other cell model of lung 
origin or from other organs (e.g. Caco-2), and with absorption kinetics in isolated lungs or 
experimental rodent models.
16-18
 The results obtained, however, were frequently 
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contradictory, which points to a certain heterogeneity in culture conditions, study protocols 
and marker selection.  
Some of the open questions remaining are: do we need organotypic cell culture models? 
The changing cellular phenotype along the respiratory tree makes it plausible to have 
different models available representing the large airways, small airways and alveoli, 
respectively, but are different models for different lung sections really required? Do 
complex co-culture models offer benefits over mono-cultures? Is the predictive power of 
the currently available models sufficient to allow IVIVC? Do we need a “Caco-2-like” gold 
standard for the lungs? Do transport study conditions matter? 
 
Precision-cut lung slices for profiling of inhaled compounds 
Development of locally acting inhaled drugs for the treatment of respiratory disease relies 
on the optimisation of compound and/or formulation properties to achieve retention in the 
lung that provides a sufficient level and duration of local exposure.
19
 Whilst most small drug 
molecules are rapidly absorbed across the pulmonary epithelium, molecular properties such 
as lipophilicity and basicity which are normally associated with increase tissue binding,
20
 
have been found to be also associated with enhanced lung retention.
19
 This observation 
triggered the investigation of how the extent of lung tissue binding, determined in precision-
cut lung slices, relates to lung retention and the effect duration of inhaled bronchodilators. 
Using a framework originally developed for studying brain tissue
21
 lung tissue binding 
described as the unbound drug volume of distribution in the lung (Vu,lung) was found to be 
lower for salbutamol (2.2 ml/g) than for longer acting β2-adrenergic bronchodilators 
including the AZD3199 (2970 ml/g), suggesting that binding is a drug property that may be 
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relevant to profile and modulate in the optimisation of inhaled drugs. Further insight to the 
mechanisms of lung tissue binding was provided by modulation of lysosomal pH using 
monensin: a substantial proportion of basic bronchodilators was found to reside in these 
compartments and to slow down the rate of drug release from tissue as studied in the 
slices.
22
 
Moreover it was shown that ipratropium, a quaternary amine and an anti-muscarinic 
bronchodilator, had an accumulation in lung slices that was 8-fold higher than what would 
be expected from lung tissue binding determined in homogenate of lung tissue. This points 
to the existence of a carrier mechanism in its cellular accumulation. Interestingly, 
ipratropium is a substrate for OCT and OCTN transporters
23
 and the intracellular 
accumulation of the prototypic OCT substrate MPP
+
 was 100-fold higher then binding in lung 
homogenate.
24
 Whilst both beta-agonist
25
 and beta-antagonists
26
 are also substrates for 
OCT transporter the contribution to cellular accumulation is likely lower. 
Besides providing an integrated experimental system to predict lung retention for certain 
classes of drugs, the specific information of lung tissue binding obtained from slices is can be 
integrated with other measured drug or formulation properties through physiologically 
based pharmacokinetic (PBPK) modelling by which the complex interplay between drug 
properties and lung physiology can be explored and understood. PBPK modelling also bears 
promise for scaling inhalation pharmacokinetics from animals to man.
27,28
 
 
Isolated and perfused lung models 
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Absorptive clearance of drug from the lungs is important for the efficacy and safety of 
inhaled medicines.
29,30
 Transporters have the potential to significantly influence drug 
absorption, but to date most of the experimental evidence for the presence and impact of 
drug transporters in the lungs comes from immunohistochemical identification of 
transporters in lung tissue and in vitro studies using respiratory epithelial cell cultures, 
respectively
14,15,31,32
 Such techniques cannot show the influence of transporters on 
pulmonary absorption – for this, air to blood solute transfer in intact lungs must be 
measured. 
Isolated perfused lungs offer unique opportunities to investigate the effect of drug 
transporters on lung permeability.
33
 In this technique, the lungs are isolated from the 
systemic circulation, perfused via the pulmonary circulation and ventilated via the trachea. 
Using isolated perfused lungs, it is possible to deliver precise concentrations of transporter 
substrates/inhibitors, measure bi-directional drug transfer (from lung to perfusate and 
perfusate to lung), pre-administer transporter inhibitors and use inhibitors in concentrations 
and combinations that are not possible in vivo. Whilst rat lungs are the most commonly 
used, it is possible to use the lungs of genetic knockout mice
34
 and lobes of human lungs.
35
 
Intrinsic and formulation-driven pharmacokinetics have been investigated following 
pulmonary administration of drugs to isolated perfused lungs. The rate and extent of drug 
transfer from airway to perfusate has been used to establish relationships with molecular 
properties,
16,36
 permeability in epithelial cell models
16,18
 and drug absorption in vivo.
16
 The 
effectiveness of a variety of absorption-modifying drug delivery strategies on absorptive 
clearance from the lungs has been investigated, including polymer microparticles,
37
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liposomes,
38
 sequence-specific phage display-derived peptide conjugated dendrimers,
39
 and 
drug-ester polymer conjugates.
40
 
Isolated perfused lungs have been used less extensively to study the impact of drug 
transporters on absorptive clearance. Airway to perfusate transfer of losartan, a P-
glycoprotein substrate, was not retarded in absorptive permeability in isolated rat lungs.
16
 
This finding was consistent with rapid the pulmonary absorption of losartan in vivo;
41
 
similarly, no effect on the absorption of another P-gp substrate, digoxin, has been reported 
in MDR1a-deficienct mice.
42
 However, subsequent detailed investigations have 
demonstrated convincingly using isolated perfused lungs with inhibitors and genetic 
knockout that the impact of P-gp on absorptive pulmonary permeability is substrate specific 
(see below).
41
 The OCT/OCTN transporter substrates ipratropium and L-carnitine have been 
shown to transfer into the pulmonary circulation of isolated rat lungs by passive processes 
rather than active uptake.
43
 However, the effect of methacholine on transport of β-agonists 
through competition for organic cation/carnitine transporters has been demonstrated in 
human lungs and linked to lung mechanics.
35
 In other studies, active transport in isolated rat 
lungs has also been demonstrated for IgG transported by neonatal constant region fragment 
receptor
44
 and the absorptive permeability transport of polyhydroxyethylaspartamide.
45
 To 
fully exploit the potential of isolated perfused lungs to study the influence of drug 
transporters, it would be useful to establish best practice in performing such studies, e.g. 
demonstration of saturation / concentration-dependency, use of inhibitors, controls and 
genetic knockouts, confirmation of findings using complimentary techniques and the 
demonstration that drug kinetics link to effect on lung mechanics.  
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A novel Quantitative Structure-Activity Relationship (QSAR) model to accurately predict 
pulmonary absorption 
A literature analysis of the physicochemical properties of respiratory drugs concluded that 
inhaled respiratory drugs have a higher hydrogen bonding capacity, polar surface area and 
molecular weight and lower lipophilicity compared to oral respiratory drugs.
46
 The authors 
also concluded that inhaled drugs with different pharmacological action occupy distinct 
property space which may limit the application of this information to the design of 
compounds for novel targets of most diverse respiratory disease.  
To facilitate inhaled drug design for more novel respiratory targets a novel in silico model was 
constructed using the largest, diverse and relevant pulmonary absorption data set available 
to date, combining both marketed inhaled drugs and novel inhaled compounds.
36
 A 
pulmonary absorption dataset generated using the isolated and perfused rat lung (IPRL) ex 
vivo model, for 82 drug discovery compounds and 17 marketed drugs, was used to build a 
novel Quantitative Structure-Activity Relationship (QSAR) model based on calculated 
physicochemical properties. The model predicted the percentage of the solubilised fraction 
of the dose, crossing the lungs into the perfusate over a 20 minute timeframe, following 
intra-tracheal instillation as an aqueous solution/suspension. A further 9 compounds were 
used to test the model’s predictive capability, with the QSAR model performing well on this 
“test set” with a predicted versus observed correlation of R
2
 = 0.85, and >65% of 
compounds correctly categorised. Calculated descriptors associated with permeability and 
hydrophobicity positively correlated with pulmonary absorption, whereas those associated 
with charge, ionisation and size negatively correlated. These findings were in keeping with 
literature describing physicochemical drivers of pulmonary absorption for a variety of 
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compounds.
41,47
 The novel QSAR model described can replace routine generation of IPRL 
model data for ranking and classifying compounds prior to synthesis therefore facilitating 
compound design through improved prediction of pulmonary absorption.
36
 It will also 
provide scientists working in the field of inhaled drug discovery with a deeper understanding 
of the physicochemical drivers of pulmonary absorption based on a relevant respiratory 
compound dataset. 
 
Computer based mechanistic models as a means to understand the impact epithelial 
permeability/transport on local and systemic drug exposure after inhalation 
Effective drug design requires a means to predict the impact of changes to product, material 
and molecular properties on the clinical performance of the medicine. Lately, computer 
based mechanistic models have shown promise. For instance, it was demonstrated that the 
clinically observed variation in rate and extent of absorption into the systemic circulation of 
a poorly soluble inhaled drug could be rather accurately predicted based on deposition 
pattern, dissolution rate and molecular physiochemical properties for a range of 
formulations and devices.
48
 Using the same mechanistic model (Gastroplus
TM
 9.0, 
Simulations Plus Inc., Lancaster, CA), extent and rate of systemic absorption was simulated 
as a function of: Deposition region; Solubility and Permeability (Figure 1). 
Results show that the extent and rate of absorption follow a pattern with respect to the 
impact of solubility and permeability which is akin to that of an oral drug. A rough 
comparison with the oral biopharmaceutical classification system
49
 revealed that: 
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• BCS1 like drugs (high permeability and high solubility) are generally rapidly and 
completely absorbed from peripheral lung regions. It is likely that these drugs would 
show limited lung targeting 
• BCS4 like drugs (low permeability and low solubility) are generally expected to be very 
poorly absorbed from conducting airways regions as result of mucociliary clearance. It 
is likely that these drugs may demonstrate a very poor effect in conducting airway 
regions. 
• BCS2/3 like drugs show some promise in terms of having some conducting airway 
bioavailability and a delayed absorption rate. This is likely the classes of compounds 
where we would expect to find most successful inhaled drugs. Nevertheless, the 
predicted low uptake (F) in large (0.1 – 0.4%) and small airways (3.4 – 11.6%) would 
put emphasis on highly potent drugs, especially given the low doses of standard 
inhalation formulations (cf. Figure 1). 
Overall, simulation results indicated that the clinical property of an inhaled medicine would 
(as could be expected) be very dependent on deposition pattern, but also on the interplay 
between solubility, permeability (and obviously target affinity).  
The heterogeneity of the lung (ranging from large, low permeable, mucociliary cleared 
conducting airways to the large-surface, highly permeable, highly perfused, alveolar gas 
exchange region),
50
 could be expected to generate regional differences in active drug 
concentration time profiles.
48
 For instance, selective local targeting of fluticasone 
propionate to conducting airway tissue was suggested to explain its observed local clinical 
efficacy in absence of total lung targeting (as measured by receptor occupancy).
27
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Although computer-based mechanistic modelling thus show significant promise in bringing 
about a better understanding of local drug tissue levels in relation to drug and product 
properties, access to good quality input parameters is vital. Today, airway permeability and 
the impact (if any) of active transport in airways is among the least understood of these 
parameters. Especially, in conducting airways, a region of significant clinical importance, 
airway permeability could govern both extent and rate of absorption and should therefore 
be further investigated.  
 
Drug transporter effects on pulmonary PK – case studies 
P-glycoprotein transport in the lungs 
P-glycoprotein (P-gp), encoded by the MDR1 gene in humans and the mdr1a and mdr1b 
genes in rodents, is amongst the most widely studied pharmaceutically relevant transport. 
P-gp substrates cover a broad range of drug classes and physicochemical properties 
although they tend to be lipophilic or amphipathic.
51
 
Evidence for P-gp expression within whole lung includes both mRNA and protein data in 
both humans and rodents
52-58
 (reviewed in
14,15,31,59
), although indications are that the lung 
displays lower levels of P-gp than in other tissues normally associated with pharmaceutical 
barrier functions. However, it is the spatial microanatomic localisation of P-gp to lung 
epithelium that needs to be considered: P-gp expression is recognised at the luminal surface 
of bronchial/bronchiolar epithelium
54-59
 and within alveolar epithelium.
54,55
 Nevertheless, 
the impact of P-gp upon pulmonary PK of inhaled drugs is poorly understood, and requires 
experiments performed in the intact lung where anatomically accurate tissue architecture is 
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maintained and appropriate parallel processes of clearance from the airways are preserved, 
including studies performed in isolated perfused organ models.  
Using an IPRL model Kuhlmann et al. in 2003 reported P-gp to limit the transport of a P-gp 
substrate, idarubicin, from the pulmonary circulation into lung tissue,
60
 indicative of P-gp 
expression within pulmonary capillary endothelial cells. In 2004, Roerig et al. using a rabbit 
model made a similar report for rhodamine 6G. However, these findings have not been 
corroborated.
61
  
Functional studies that directly or indirectly address airway to blood absorption and the 
impact of P-gp include: Tronde et al. where as part of a broader study of pulmonary 
absorption and drug structural properties the extent of absorption for the P-gp substrate 
losartan was reported to be >90% from the airways.
41
 In 2008, Manford et al.
 
reported the 
pulmonary absorption of the P-gp substrate digoxin to remain unchanged in CF-1 mice, 
which display spontaneous mdr1a knockout, although retaining mdr1b expression.
42
 In an 
IPRL model the same group reported that co-administration into the airways of a P-gp 
inhibitor had no effect upon the pulmonary absorption profile of digoxin.
62
 Contrary to this, 
a similar study in the IPRL showed a significant increase in the absorption of the P-gp 
substrate rhodamine 123 when co-dosed with the P-gp inhibitor, GF120918.
63
 
Subsequently, a study was undertaken in both IPRL and isolated perfused mouse (IPML) lung 
models that began to explore the above divergent findings.
34
 Using a comparatively small 
panel of five P-gp substrates the impact of P-gp upon airway instilled P-gp substrates 
(including the archetype digoxin and rhodamine 123 molecules) resulted in disparate 
outcomes with some substrates affected by P-gp and others not. From here the same group 
used genetic knockout P-gp mice in an IPML model and examining a much broader panel 
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(i.e. 18 molecules) of P-gp substrates instilled into the airways (Price et al. unpublished 
observation). The outcome for this larger panel again showed divergent outcomes between 
the substrates separating into two distinct sub-populations; those whose pulmonary 
absorption was affected by P-gp and those unaffected. These polarised groupings could be 
entirely distinguished by their differing computed physicochemical properties and not by 
more global biological properties such as P-gp binding affinity (Km) or turnover (Vmax). In 
general the more polar the P-gp substrate the less its pulmonary absorption was impacted 
by P-gp. To put this in context, the same panel was tested in intestinal absorption studies in 
the P-gp knockout and control mice. Here no distinct sub-populations could be identified. 
The only study on P-gp effect on pulmonary absorption in man found that oral verapamil 
increased the area under the curve (AUC) of inhaled umeclidinium bromide and vilanterol by 
approximately 40%.
64
 In that study, however, the concentrations of inhalants were a 
multiple of the approved clinical dose and the timing between administration of the oral 
inhibitor and the begin of the inhalation manoeuvre was suboptimal.  
In summary, work is beginning to identify specific physicochemical properties for P-gp 
substrates that predict if their absorption from the lung may be affected by P-gp; these 
same physicochemical signatures do not predict the effect of P-gp upon intestinal 
absorption.  
 
Interaction of organic cation transporters with bronchodilators in vitro, ex vivo and in vivo 
Organic cation transporters (i.e. OCT1-3 and OCTN1, 2) belong to the SLC22 gene-family.
65
 
The majority of inhaled drugs, e.g. bronchodilative β2-adrenergic agonists and anti-
muscarinics are either permanent cations or bases, whilst several inhaled corticosteroids 
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have been reported to be OCT inhibitors (Table 1). Therefore, this family of transporters has 
received considerable attention in the past 10 to 15 years.
66
 The vast majority of data have 
been generated in cell-based in vitro models, often reporting conflicting findings.
15
 This 
might be explained by different culture conditions of primary cells and cell lines which can 
result in changes in transporter expression and activity. Organic cation accumulation and 
absorption in lung tissues, however, was also studied in lung slices and perfused organ 
models, respectively.
24,35
 An involvement of OCT/N transporters in the pulmonary 
absorption of salbutamol was proposed already in 2005,
67
 and although many publications 
were published demonstrating OCT/N expression and activity in lung tissues and cell 
cultures,
68-70
 the molecular identity of the transporters responsible was not clarified until 
recently, when functional studies using OCT over-expressing expression systems showed 
that OCT1 and OCT3 exhibit high affinities for β2-adrenergic agonists.
25
 Direct evidence, 
using either radiolabelled probes, RNAi or overexpression studies demonstrating evidence 
on the contribution of OCTN1, 2 in β2-adrenergic agonists transport is still outstanding. 
OCTN contribution to the uptake of ipratropium, on the other hand, has been shown in vitro 
and in vivo,
23,71
 but the role of the transporters in pulmonary transport and lung PK of anti-
cholinergics is still controversially discussed.
43
 
 
Functional expression of PEPT2 and its regulation in alveolar epithelial cells 
The di- and tri-peptide transporters, PEPT1 (SLC15A1) and PEPT2 (SLC15A2) transport 
various peptidomimetic drugs such as β-lactam antibiotics and antivirals, and have an 
important role, for example in the absorption of these drugs from the intestine. PEPTs are 
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secondary active transporters, and transport their substrates coupled with an 
electrochemical proton gradient.
72
  
PEPT2 is functionally expressed in alveolar epithelial type 2 cells, but not in type 1 cells.
73
 
However, the widely used cell lines with alveolar epithelial type 2-like phenotype such as 
A549 (a cell line derived from human lung adenocarcinoma) and RLE-6TN (a cell line derived 
from rat normal lung) do not have substantial PEPT2 activity. The human distal lung 
epithelial cell line, NCI-H441 has recently been reported to have PEPT2 activity.
74
 In NCI-
H441 cells, PEPT2 protein is expressed on the apical membrane and facilitates the uptake of 
PEPT2 substrates into the cells. At this moment, the pharmacological role of alveolar PEPT2 
in the pulmonary absorption of peptidomimetic drugs after inhalation is not entirely clear. 
Physiologically, PEPT2 might be involved in the innate immune response via a nucleotide-
binding oligomerisation domain 1 (NOD1)-dependent mechanism,
75
 as it has been shown 
that the bacterial dipeptide, γ-D-glutamyl-meso-diaminopimelic acid (γ-iE-DAP), an initiator 
of this response, can be taken up by PEPT2. It is very interesting and important to further 
clarify the pharmacological and physiological roles of PEPT2 in the human lung. 
 
Implications of the carrier-mediated transport of nicotine in lung and other tissues 
Although nicotine is rapidly absorbed from the lung and distributed to the brain after 
tobacco smoking,
76
 our knowledge of the transport mechanism by which nicotine crosses 
the alveolar epithelial barrier and blood-brain barrier is incomplete. Nicotine uptake by 
A549 human carcinoma-derived cells with an alveolar epithelial type 2 cell-like phenotype 
was found to be time-, temperature-, and concentration-dependent with a Michalis-Menten 
constant of 50 µM, suggesting that a carrier-mediated process is involved in nicotine 
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transport in alveolar epithelial cells. Nicotine absorption was reduced by hydrophobic 
cationic drugs such as verapamil and pyrilamine, whereas typical substrates and inhibitors of 
organic cation transporters did not show inhibitory effect.
77
 The transport mechanism of 
nicotine in alveolar epithelial cells shows great similarity to that in a brain capillary 
endothelial cell line in vitro.
78
 This evidence suggests that the newly identified organic cation 
transport system is involved in nicotine transport process in lung and the blood-brain 
barrier. Once taken up by alveolar epithelial and brain endothelial cells, nicotine could 
further be efflux to the blood from the lung and to the brain from the blood, respectively. 
Currently, however, little is known regarding the mechanisms underlying the efflux of 
nicotine at the basolateral membrane of alveolar epithelial and brain endothelial cells.  
Nevertheless, this transport might offer the opportunity of delivering cationic drugs to the 
brain after inhalation. 
 
Pulmonary transporters in the drug disposition of antibiotics 
When tissue distribution is only governed by passive diffusion, unbound AUC in plasma and 
tissue extra-cellular fluid (ECF) should be identical, whereas in the presence of active efflux, 
unbound AUC should be lower in tissue ECF than in plasma. Drug concentrations can be 
measured within lung epithelial lining fluid (ELF) after broncho-alveolar lavage (BAL) from 
laboratory animals or humans, and correction for dilution can obtained by measuring urea 
in plasma and BAL. Because albumin concentrations in the alveolar lining fluid are extremely 
low compared with those in plasma under normal condition (<10% of plasma), one can 
assume that estimated ELF concentrations correspond to unbound drug concentrations.
111
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A series of experiments has recently been initiated using well controlled experimental 
conditions, in order to develop a biopharmaceutical classification of nebulised antimicrobial 
agents, based on their water solubility and membrane permeability.
79-83
 Healthy rats were 
used for these experiments. Antibiotics were administered intravenously or nebulised using 
a Penn-Century MicroSprayer®. This system allows most of the dose to reach the bronchial 
alveoli where the drug can be systemically absorbed. Simultaneous BAL and plasma 
sampling was conducted at various time points post-dosing for assessment of drug 
concentrations. The route of administration had a major effect on lung PK for antibiotics 
presenting low membrane permeability (and therefore low and even virtually negligible oral 
bioavailability allowing only parenteral administration in clinical practice), such as colistin,
80
 
tobramycin
81
 or aztreonam,
82
 with much higher ELF concentrations after nebulisation when 
compared to intravenous administration at the same dose, and much higher ELF 
concentrations than unbound plasma concentrations after nebulisation. By contrast, the 
route of administration had no detectable effect on ELF and unbound plasma 
concentrations for antibiotics with relatively high membrane permeability (and therefore 
high oral bioavailability allowing oral administration in patients), such as ciprofloxacin or 
moxifloxacin.
79
 Yet the profound differences observed between compounds were related to 
differences in membrane permeability, essentially controlled by passive diffusion and 
irrespective of active transport phenomena.  
However, the higher ELF than unbound plasma concentrations observed with moxifloxacin 
independently of the route of administration suggested or at least were consistent with an 
active efflux transport (Figure 2). Moxifloxacin is highly permeable and therefore, its 
distribution equilibrium occurs rapidly after both intravenous administration and 
nebulisation. Nonetheless, moxifloxacin is also a P-glycoprotein substrate,
84
 which could 
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explain why ELF concentrations were higher than unbound plasma concentrations. Although 
unlikely, one cannot totally exclude that ELF concentrations may have been over-estimated 
after moxifloxacin present within cells (e.g. macrophages) was released to ELF during BAL 
sampling. In fact, such differences between ELF and unbound plasma concentrations were 
not observed with ciprofloxacin, also a known P-gp substrate. Therefore, the in vivo effect of 
P-gp on moxifloxacin lung PK should be further confirmed using appropriate knock-out 
animals. Alternatively, interaction studies with potent, specific and non-toxic competing P-
gp substrates or inhibitors could be conducted in whole animals or/and using an isolated 
and perfused lung model. For low-permeability drugs it will take time to reach equilibrium 
distribution and therefore, the effect of an efflux transport system on the lung PK would 
probably be observable after multiple dosing at steady-state, but not after single dose 
administration, which was confirmed by PK studies. 
 
Transporters as drug targets 
Organic cation transporter OCTN1 as possible target for lung pathology 
The SLC22A4 gene has been identified to be associated with several diseases such as 
rheumatoid arthritis,
85
 Crohn’s disease,
86
 autoimmune thyroid disease
87
 and recessive non-
syndromic hearing loss DFNB60 in humans.
88
 This implies that the OCTN1 transporter could 
play a role in onset and/or deterioration of these diseases although little information is 
available on the molecular mechanisms. Since OCTN1 was originally identified as a 
xenobiotic transporter, which accepts various types of organic cations as substrates in vitro, 
identification of its substrate(s) in vivo may help understanding of how this transporter is 
associated with those diseases. Thus octn1 gene knockout (octn1
-/-
) mice were generated 
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and metabolome analysis of blood and several organs in both wild-type and octn1
-/-
 mice 
was carried out, leading to the identification of the food-derived antioxidant, ergothioneine 
(ERGO) as the physiological substrate of OCTN1.
89
 This finding was in agreement with 
metabolome analysis using SLC22A4 gene transfected cell lines, which originally identified 
ERGO as OCTN1 substrate.
90
 ERGO is furthermore demonstrated to be possible biomarker 
substance in both rheumatoid arthritis
91
 and Crohn’s disease.
92
 
Since oxidative stress is associated with various types of inflammatory diseases, speculating 
about a protective role for OCTN1 by transporting ERGO into cells to reduce oxidative stress 
is warranted. This protective role of OCTN1 was recently studied in tobacco smoke-induced 
chronic obstructive pulmonary disease (COPD).
93
 Exposure to tobacco smoke leads to 
oxidative stress, which contributes to alveolar wall destruction, mucus hyper secretion, 
inflammation and defective tissue repair. Semi-quantitative PCR and immunoblot revealed 
elevated expression levels of catalase, thioredoxin and sulfiredoxin-1 following treatment 
with ERGO in NCI-H441 cells. Moreover, lower levels of oxidative stress were observed in 
cells, which were cultured in the presence of ERGO prior to the exposure to cigarette smoke 
extract. When exposed to room air, octn1
-/-
 mice showed little differences compared to 
wild-type mice. However, numbers of total cells and PNMs in BAL fluid as well as increased 
alveolar damage and increased inflammatory markers were observed in octn1
-/-
 mice 
compared to wild-type mice, when exposed to second-hand smoke. These data suggest that 
ERGO can protect lung epithelial cells from oxidative damage and consequently, variants of 
OCTN1 might play a role in the pathogenesis of tobacco smoke-induced COPD by regulating 
ERGO transport. 
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Pathophysiological role of prostaglandin transporter OATP2A1/SLCO2A1 in pulmonary 
fibrosis 
Prostaglandin (PG) E2 is a bioactive lipid produced from arachidonic acid via the 
cyclooxygenase (COX)-PGE synthase (PGES) pathway. The prostaglandin transporter, 
OATP2A1 (aka PGT) encoded by the SLCO2A1 gene has been characterised as an importer 
with high affinity to PGE2, PGF2α and PGD2 at plasma membranes.
 94,95
 Recent genome-wide 
association studies indicate a link of loss-of-function mutations in SLCO2A1 with primary 
hypertrophic osteoarthropathy
96
 and chronic non-specific multiple ulcers of the small 
intestine.
97
 Since PGE2 is anti-fibrotic to lung stromal cells
98
 and OATP2A1 is expressed 
functionally in mouse lungs
99
 and the human bronchial epithelial BEAS-2B cells,
100
 the effect 
of the absence of Slco2a1 on pulmonary fibrosis in intra-tracheally (i.t.) bleomycin-injected 
mice was studies.
101
 Immunohistochemistry showed that abundant expression of Oatp2a1 
in mouse type 1 alveolar epithelial cells (AT1), and PGE2 uptake was almost diminished in 
Slco2a1
-/-
mice-derived AT1-like cells. Bleomycin-induced interstitial pneumonia and fibrosis 
became more severe in Slco2a1
-/-
 mice, manifesting greater airway infiltration of 
inflammatory cells, collagen deposition and TGF-β1 signalling-related gene expressions (e.g. 
Tgf-b1 and Pai-1). Two weeks after the i.t. injection, Western blot analysis demonstrated a 
significant activation of protein kinase C (PKC)-δ in the lungs of Slco2a1
-/-
 mice, which 
contributes to an excessive production of extracellular matrix. Moreover, PGE2 levels 
approximately 5-fold elevated significantly in BAL fluid of bleomycin-injected Slco2a1
-/-
 mice, 
compared to that of wild type (WT) counterparts, although no other eicosanoids were found 
to increase in the BAL fluid by means of eicosanoid targeting metabolomics analysis. On the 
other hand, PGE2 concentration in lung homogenates tended to decrease in Slco2a1
-/-
 mice. 
Accordingly, altered PGE2 disposition in the lung of Slco2a1
-/-
 mice may contribute to 
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aggravation of pulmonary fibrosis induced by bleomycin. It is hypothesised that PGE2 
released into alveolar lumen from epithelium and inflammatory cells infiltrated airway could 
transverse across AT1 cells into the lung interstitium via luminal OATP2A1, and then, inhibits 
fibroblast activation. This hypothesis is also supported that fact that PKC-δ was negatively 
regulated by c-AMP produced by PGE2 signals in human lung fibroblasts.
102,103
 Moreover, it 
was recently found that intracellular OATP2A1 mediates exocytosis of PGE2 from murine 
macrophages;
104
 therefore, PGE2 autocrine signal may be altered in infiltrated monocytes 
and involved in severe inflammation. Revealing the precise role of OATP2A1 in tissue 
remodelling, which has been unappreciated to date, may provide a new rationale for 
mechanism of action of PGE2 and possibly for pulmonary fibrosis. 
 
Summary and conclusions 
Lung transporter research is conducted in a small number of academic and industry 
laboratories with wider interest limited pending the first case studies to illustrate that drug-
transporter interactions in the lungs have clinical impact. Although some studies have 
shown effects of transporters on drug absorption from the lungs, there are no scientific 
reports to the authors’ knowledge that provide evidence of a significant impact on target 
engagement or drug activity in the lungs. However, the potential impact that transporters 
may have in determining local free drug concentrations in target lung compartments (and 
thus drug action in the lungs) may be missed by insensitive measures such as net lungs-to-
blood absorptive clearance. The potential for inhaled medicines to affect normal 
physiological processes, i.e. those mediated via the endogenous substrates of transporters, 
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provides a further reason to understand better the way in which inhaled drugs interact with 
transporters during their residence in the lungs.  
A barrier to progress in studying drug transporters in the lungs is that techniques required 
for evaluating impacts on local drug disposition are not routinely available or relatively 
recently developed. This includes methods to deliver appropriate doses and distributions of 
aerosolised drug accurately into the lungs of small animals or isolated perfused lungs, 
methods to study receptor occupancy as a surrogate for drug action following 
administration of drugs to the lungs and mechanistic modelling approaches, which can 
discern the impact of transporter kinetics in the context of competing pathways for drug 
clearance. Such models can be used to generate hypotheses for experimental testing and 
develop deeper understanding of inhaled drug biopharmaceutics. Priorities for further 
research in the field have been laid out previously by Gumbleton and colleagues in 2011 and 
it is interesting to revisit these to see what progress has been made (Table 2).
14
  
The advantages and limitations of the different systems in which lung transporters are 
studied should also be considered (Table 3), so that these can be used in complementary 
study designs to investigate transporter interactions using triangulation to confirm 
hypotheses and observations. Cell cultures provide convenient systems in which 
transporters are expressed and can be characterised for their substrate specificity, drug-
interactions and kinetics. Ex vivo lungs enable drug transport to be studied in a model that 
possesses the architecture of the lungs and can be combined with delivery by inhalation and 
measurement of lung function. For example, the IPL has been used to examine the link 
between PK and lung mechanics.
35
 In vivo studies permit less precise control of 
experimental conditions, but are the ultimate proof of impact of transporter actions.  
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In conclusion, it is well established that transporters for which licensed inhaled molecules 
are substrates are present in the lungs. New drug candidates for treating respiratory disease 
may include different chemical classes, with different transporter affinities. Furthermore, 
the molecularly diverse drugs that may be delivered via the lungs for systemic action may 
also bring different transporters into play. The physiological role for these transporters may 
provide clues regarding their likely impact on local disposition of drugs in the lungs. The 
influence of disease on these transporters may also be important. For drugs that have 
targets in the lungs, the effect of transporters on inhaled drug biopharmaceutics is not 
adequately investigated if only systemic exposure is measured and carefully designed 
studies are needed to measure effects in the lungs themselves. 
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Figure Legends 
Figure 1. Impact of deposition, solubility and permeability on extent and rate of systemic 
absorption.  
Figure 2. Concentration-time profiles of moxifloxacin following i.v. administration and 
administration of the nebulised form in plasma (red line, closed symbols) and in ELF (blue 
line, open symbols), predicted from simultaneous PK modelling of plasma and ELF data. 
Symbols represent means ± SD concentrations measured in plasma and ELF. Taken from
79
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Table 1. List of FDA-approved drugs for inhalation with reported organic cation transporter 
interactions (adapted from
15, 110
)  
 
Bold face indicates drugs which act as inhibitors 
*, Interactions were found in non-lung tissues or cells 
Compound Drug Class Transporters 
Salbutamol β2-Adrenergic agonist OCT1, OCT3, OCTN1(?), 
OCTN2(?)  
Beclomethasone diproprionate Corticosteroid OCT1, OCT2 
Budesonide Corticosteroid OCT1-3 
Ciprofloxacin Antibiotic OCT-3, OCTN2* 
Fenoterol β2-Adrenergic agonist OCT1, OCT2 
Fluticasone propionate Corticosteroid OCT2, OCT3 
Formoterol β2-Adrenergic agonist OCT1, OCT3, OCTN2 
Indacaterol β2-Adrenergic agonist OCT1, OCT2 
Ipratropium bromide Anticholinergic OCT2, OCTN2* 
Levofloxacin Antibiotic OCT2* 
Olodaterol β2-Adrenergic agonist OCT1* 
Pentamidine Antiprotozoal OCT1-3* 
Salmeterol xinafoate β2-Adrenergic agonist OCT1, OCT3 
Terbutaline β2-Adrenergic agonist Oct1*, Oct2 * 
Tiotropium bromide Anticholinergic OCT2, OCTN2* 
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?, Contradictory information  
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Table 2. Research priorities identified by Gumbleton et al. 2011.
14
 
Research priorities Examples of progress 
Identify transporters in human lungs and other species 
used in preclinical evaluation of inhaled medicines 
Summarised by Nickel et al. 2016
15
 and 
Gustavsson et al. 2016
32
 
Map levels and locations of transporter expression 
within the lungs 
Summarised by Nickel et al. 2016
15 
and 
Gustavsson et al. 2016
32
 
Demonstrate the impact of transporters on drug 
retention or disposition in the lungs after inhalation 
Data on P-gp effects from IPL and in vivo 
animal work, e.g.
34,63,71
 
Study the effect of transporters on accumulation of 
drug in the lungs from the systemic circulation 
Forbes has investigated uptake via the 
polyamine transporter (unpublished data); 
Paraquat accumulation in lung tissue
105
  
Do inhaled drugs alter transporter expression or 
function (thereby affecting normal physiology) 
No evidence yet  
Clinical impact of transporters, e.g. drug-drug 
interactions, effect of disease, inter-individual 
variability 
Methacholine caused decrease of β2 
agonist absorption in human IPL;
35
 
Oral verapamil increased AUC of inhaled 
umeclidinium and vilanterol in human 
volunteers
64
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Table 3. Experimental models for measuring effects of transporters on drug disposition in 
the lungs 
Experimental system Advantages Limitations  
Respiratory cell cultures • Primary cell cultures and 
many cell lines available 
• High capacity, readily 
available 
• Measurement of transport or 
cell uptake 
• Measurement of metabolism 
• Molecular identification of 
pathways possible 
• Usually only single cell type 
• Many clearance mechanisms 
missing  
• Relevance to lung effects 
unclear? 
 
Isolated perfused lungs • Human lung lobes can be 
used 
• Can be linked to lung function 
measurement 
• Can study air to blood and 
blood to lung transport 
• Can use inhibitors in high 
concentrations, controlled 
concentrations 
• Use of genetically modified 
animals possible 
• Species differences unclear 
• Access to human lung is 
limited 
• Short study duration 
• Not trivial to set up 
In vivo experiments • Lung function can be 
measured 
• Disease models can be used 
• Use of genetically modified 
animals possible  
• Use of inhibitors and 
concentrations limited 
• Studies in humans are limited 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
